CJC (No DAC) + IPA Stack No DAC · 10mg
A co-lyophilized blend of a GHRH analog and a selective GHRP, supplied lyophilized for in vitro GHRH-R and GHS-R1a co-activation research.
What is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin (No DAC) is a co-lyophilized blend of two synthetic peptides that act as a dual growth-hormone secretagogue system. CJC-1295 (no DAC) is a modified GRF(1-29), a growth-hormone-releasing-hormone (GHRH) analog that binds the GHRH receptor on pituitary somatotrophs, while Ipamorelin is a selective growth-hormone-releasing peptide (GHRP) that binds the ghrelin receptor (GHS-R1a). Because the two peptides engage different receptors on the same cells, laboratories use the blend as a reference GHRH-plus-GHRP combination for studying synergistic GH release.
Research areas where laboratories buy this blend for in vitro work include GHRH-R and GHS-R1a co-activation studies on pituitary somatotrophs, GH-release synergy experiments comparing single versus dual secretagogues, cAMP and calcium-mobilization signaling assays, and selectivity profiling against ACTH, cortisol, and prolactin readouts. Neither component is an FDA-approved drug.
Frequently paired in growth-hormone axis research
Frequently Asked Questions About CJC-1295 + Ipamorelin
It is the reference GHRH + GHRP dual-secretagogue combination for studying synergistic GH release on pituitary somatotrophs — pairing GHRH-receptor agonism (CJC-1295 no DAC) with ghrelin-receptor agonism (Ipamorelin) in one experimental system. Common uses include GH-release synergy experiments, cAMP and calcium-mobilization assays, and selectivity profiling against ACTH/cortisol/prolactin.
Each peptide is released at ≥ 99% by HPLC with LC-MS-confirmed identity, against ISO/IEC 17025-accredited testing covering HPLC purity, LC-MS identity, heavy metals, sterility, and endotoxin. The lot-matched COA is published in the public library against the lot number printed on the vial.
Use sterile or bacteriostatic water at neutral pH; add diluent slowly down the vial wall and avoid vortexing. Prepare working dilutions immediately before use, and for sterile cell-culture work filter through a 0.22 µm low-protein-binding filter. Store reconstituted material at 2 to 8 °C, or aliquot and freeze at − 20 °C or below.
Ipamorelin is CAS 170851-70-4 (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, a GHRP that binds GHS-R1a). CJC-1295 (no DAC) is a modified GRF(1-29) GHRH analog that binds the GHRH receptor. Identity of both is confirmed by LC-MS on each released lot.
Store the lyophilized powder at − 20 °C, desiccated and protected from light; for long-term storage − 80 °C is preferred. After reconstitution, store at 2 to 8 °C or aliquot and freeze. Avoid repeated freeze-thaw cycles.
No. The research-grade blend supplied by Kylo Peptides is for in vitro laboratory study only. Neither component is formulated, packaged, or labeled for human or veterinary use, and neither is an FDA-approved drug.
Yes. The lot-specific Certificate of Analysis is published in our public COA library and matched to the lot ID printed on the vial, covering HPLC purity, LC-MS identity, heavy metals, sterility, and endotoxin for the components from an independent ISO/IEC 17025-accredited laboratory.
CJC-1295 'no DAC' is the modified GRF(1-29) without the Drug-Affinity-Complex (a maleimide that binds albumin). Without DAC, the GHRH analog has a shorter-acting profile than DAC versions, which is the form used in this blend.
Research-grade peptides, third-party verified.
Made in the USA, third-party tested, with public lot-matched COAs. Shop the catalog, or get restock & new-compound alerts.
Shop catalog →
